Astellas Pharma Inc. has seen several significant developments, including structural changes, partnerships, financial performance updations, and new drug applications. The firm has made crucial announcements regarding its management structure, revealing a radical drug discovery method led by a new R&D Chief.
Significant growth in short interest in Astellas stock has also been observed. The company is seeking conditional approval for GA treatment in Japan and has submitted new drug applications. Despite missing recent earnings forecasts and experiencing losses, Astellas continues to make notable strides in healthcare and eye disease management. Relatedly, the company has announced collaboration with
Sangamo Therapeutics and YASKAWA to pioneer technologies for neurological diseases and cell therapy ecosystems, respectively. As part of its commitment to innovation, the company has established a New Life Sciences center in Cambridge, Massachusetts. It also presented VEOZA data at an international menopause conference. Amidst these achievements, Astellas faces legal challenges, particularly an employee indictment in China.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:18 GMT to Fri, 07 Feb 2025 08:00:00 GMT -
Rating 4
- Innovation 8
- Information 10
- Rumor -7
